세계의 암백신 시장, 백신 가격, 용량, 판매, 임상시험 전망(2029년)

“Global Cancer Vaccine Market, Vaccine Price, Dosage, Sales & Clinical Trials Outlook 2029” Report Highlights:

• Global Cancer Vaccine Market Opportunity : > USD 20 Billion By 2029
• Cancer Vaccine Market Regional Trends Insight: 10 Countries
• Cancer Vaccine Market Trends Insight By Indication: 10 Indications
• Insight On Cancer Vaccine In Clinical Trials: > 400 Vaccines
• Insight On Cancer Vaccine Commercially available in Market: > 15 Vaccines
• Cancer Vaccines Clinical Trials By Company, Country, Indication & Phase
• Approved Cancer Vaccines Price & Dosage Analysis
• Proprietary Vaccine Manufacturing Technologies By Indication

In the era of modern medicine, innovative advancements are revolutionizing the field of cancer treatment. Among these innovative approaches are cancer vaccines which are emerging as a potential strategy that is offering transformation in the treatment of cancer. Harnessing the power of immune system, these vaccines hold the promise of preventing, treating and ever eliminating various types of cancers. With the development of preventive as well as therapeutic cancer vaccines, it can be predicted that soon, cancer vaccines will hold a major share in the global cancer treatment market.

One of the most significant characteristics about cancer vaccines is their ability to provide personalized and precision medicine. Cancer vaccines can be customized to target specific antigens, mutations or signalling pathways present in a patient's tumor. By leveraging advancements in genomics and immunology, these vaccines offer a precise and targeted approach, maximizing treatment efficacy while minimizing adverse side effects.

To further enhance treatment outcomes, pharmaceutical companies have been investigating cancer vaccines in combination with other therapeutic modalities. By incorporating vaccines with immune checkpoint inhibitors, targeted therapies or chemotherapy, synergistic effects can be achieved, leading to improved response rates and long term remission. These combination approaches have demonstrated promising results in clinical trials, offering new possibilities for more effective and comprehensive cancer treatment regimes.

Furthermore, the development of cancer vaccines has been fueled by collaboration among pharmaceutical companies, research institutions and healthcare professionals. This collective effort has led to significant advancements in vaccine technology, formulation, optimization and clinical trial design and assessment. Additionally, with the support of government regulatory bodies and global health organizations, cancer vaccines have been progressing rapidly through the development of a robust clinical pipeline.

While cancer vaccines have shown promise in certain cancer types, the future holds a tremendous potential for expanding their application to a wider range of malignancies. Ongoing research is focused on developing vaccines for various solid tumors such as lung cancer, breast cancer, and ovarian cancer among several others. With each breakthrough, the spectrum of cancers that can be effectively treated or prevented with vaccines continues to expand.

As the field of cancer vaccines advances, efforts to ensure global access and collaboration will be a dominant factor. With ongoing research and development, the number of cancer vaccine candidates is increasing, targeting different types of cancers and utilizing various vaccine formulations. The period of COVID-19 determined the importance of vaccines and how effective they can be in controlling disease progression. If same robust research continues towards cancer vaccine development, it can be predicted that not only preventive vaccines but also therapeutic vaccines will enter the global market.

In 2010, Dendreon launched Provenge, making history as it became the first ever therapeutic cancer vaccine. This cell based immunotherapy was targeted towards the treatment of prostate cancer. Achieving this milestone, the entry of Provenge encouraged the growth of other therapeutic cancer vaccines in clinical development. However, therapeutic vaccines have made great advancements in recent years and the products currently in clinical trials represent an era of low toxic treatment options while also addressing several unmet needs that continue in cancer.

Therapeutic cancer vaccines are poised to revolutionize cancer treatment by leveraging the power of immune system against cancer cells. As personalized, targeted therapies, they offer the potential for long lasting responses and improved patient outcomes. By combining these vaccines with other treatment modalities and expanding their reach to a broader range of cancers, researchers are currently paving the way for future where therapeutic cancer vaccines play a pivotal role in cancer treatment. With ongoing research and development, these vaccines will continue to expand the global cancer vaccine market.

Our report provides an in depth analysis about the current research and development landscape of cancer vaccines. Moreover, the report also provides pricing and dosage information about the currently approved preventive and therapeutic cancer vaccines. Apart from this, a regional analysis containing detailed overview about the countries and the intensity with which they are developing cancer vaccines. In addition, the report also provides information about the current market opportunities and the possible future prospects that might open in the global market of cancer vaccines.

Table of Contents

1. Introduction To Cancer Vaccines

2. Mechanism Of Cancer Vaccines

• 2.1 Idiotype Cancer Vaccine Mechanism
• 2.2 Cellular Cancer Vaccines Mechanism
• 2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
• 2.4 Peptide Cancer Vaccine Mechanism
• 2.5 Tumor Host Interaction Cancer Vaccine Mechanism

3. Global Cancer Vaccine Market Overview

• 3.1 Current Market Scenario
• 3.2 Future Market Opportunity

4. Global Cancer Vaccine Market Trends By Country

• 4.1 US
• 4.2 Europe
• 4.3 China
• 4.4 Japan
• 4.5 India
• 4.6 South Korea
• 4.7 Australia
• 4.8 South America
• 4.9 Canada
• 4.10 UK

5. Cancer Vaccine Market Insight & Proprietary Vaccine Manufacturing Technologies By Indication

• 5.1 Lung Cancer
  • 5.1.1 Current Clinical Market Trends
  • 5.1.2 Proprietary Manufacturing Technology Platforms
• 5.2 Pancreatic Cancer
  • 5.2.1 Current Clinical Market Trends
  • 5.2.2 Proprietary Manufacturing Technology Platforms
• 5.3 Prostate Cancer
  • 5.3.1 Current Clinical Market Trends
  • 5.3.2 Proprietary Manufacturing Technology Platforms
• 5.4 Bladder Cancer
  • 5.4.1 Current Clinical Market Trends
  • 5.4.2 Proprietary Manufacturing Technology Platforms
• 5.5 Melanoma
  • 5.5.1 Current Clinical Market Trends
  • 5.5.2 Proprietary Manufacturing Technology Platforms
• 5.6 Breast Cancer
  • 5.6.1 Current Clinical Market Trends
  • 5.6.2 Proprietary Manufacturing Technology Platforms
• 5.7 Colorectal Cancer
  • 5.7.1 Current Clinical Market Trends
  • 5.7.2 Proprietary Manufacturing Technology Platforms
• 5.8 Glioblastoma
  • 5.8.1 Current Clinical Market Trends
  • 5.8.2 Proprietary Manufacturing Technology Platforms
• 5.9 Ovarian Cancer
  • 5.9.1 Current Clinical Market Trends
  • 5.9.2 Proprietary Manufacturing Technology Platforms
• 5.10 Human papillomavirus Associated Cancer
  • 5.10.1 Current Clinical Market Trends

6. Approved Cancer Vaccines - Price & Dosage Analysis

• 6.1 Gardasil/ Gardasil 9
• 6.2 Cervarix
• 6.3 Heplisav-B
• 6.4 PreHevbrio
• 6.5 Engerix-B
• 6.6 Twinrix
• 6.7 Recombivax HB
• 6.8 Provenge
• 6.9 Cecolin
• 6.10 CimaVax
• 6.11 Vaxira
• 6.12 Riavax
• 6.13 Oncophage
• 6.14 Mycidac-C
• 6.15 Reniale
• 6.16 Cervavac*

7. Global Cancer Vaccines Clinical Trials Overview

• 7.1 By Company
• 7.2 By Country
• 7.3 By Indication
• 7.4 By Patient Segment/Disease Stage
• 7.5 By Phase

8. Global Cancer Vaccines Clinical Trials By Company, Country, Indication & Phase

• 8.1 Research
• 8.2 Preclinical
• 8.3 Phase-I
• 8.4 Phase-I/II
• 8.5 Phase-II
• 8.6 Phase-II/III
• 8.7 Phase-III
• 8.8 Registered

9. Marketed Cancer Vaccines Clinical Insight By Company, Country &Indication

10. Competitive Landscape

• 10.1 Ayala Pharmaceuticals
• 10.2 BioNTech
• 10.3 CureVac
• 10.4 Elicio Therapeutics
• 10.5 Enochian BioSciences
• 10.6 Enterome
• 10.7 EpiThany
• 10.8 Gradalis
• 10.9 Hookipa Pharma
• 10.10 Immunitor
• 10.11 Immunomic Therapeutics
• 10.12 In3Bio
• 10.13 IO Biotech
• 10.14 ISA Pharmaceuticals
• 10.15 Jiangsu Recbio Technology
• 10.16 Mary Crowley Cancer Research Center
• 10.17 Mayo Clinic
• 10.18 Memorial Sloan-Kettering Cancer Center
• 10.19 Mendus
• 10.20 Merck
• 10.21 MGFB Bio
• 10.22 Nykode Therapeutics
• 10.23 OncoTherapy Science
• 10.24 pHion Therapeutics
• 10.25 Qu Biologics
• 10.26 Scancell
• 10.27 UbiVac
• 10.28 Vaccitech
• 10.29 VAXIMM
• 10.30 Zhongsheng Kangyuan Biotechnology